DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-073/S-024

Takeda Global Research & Development Center, Inc.
Attention: Mary Jo Pritza, MPH, PharmD
Manager, Regulatory Affairs
475 Half Day Road, Suite 500
Lincolnshire, IL 60069

Dear Ms. Pritza:

Please refer to your supplemental new drug application dated July 13, 2004, received July 14, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Actos® (pioglitazone HCl) Tablets, 15 mg, 30 mg, and 45 mg.

This supplemental application proposes to add the following sentence to the **PRECATIONS** section, **Carcinogenesis, Mutagenesis, Impairment of Fertility** subsection of the package insert:

> "Urinary tract tumors have been reported in rodents taking experimental drugs with dual PPAR α/(activity; however, ACTOS is a selective agonist for PPAR(."

We completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling text for the package insert submitted on July 13, 2004.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 21-073/S-024." Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Ms. Jena Weber, Regulatory Project Manager, at 301-827-6422.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff

7/20/04 05:49:06 PM